Piramal Pharma posts Rs 4 crore net profit in Q3FY25

Piramal Pharma on Tuesday reported net profit of Rs 4 crore in Q3FY25.

The company reported a net profit of Rs 10 crore in the corresponding quarter of the previous year.

Revenue from operation rose 13% year-on-year (YoY) to Rs 2,204 crore in Q3FY25.

EBITDA rose 6% YoY to Rs 350 crore, while EBITDA margins dropped 100 basis points to 16%.

The contract research and manufacturing services (CDMO) revenues rose 13% YoY to Rs 1,278 crore led by continued traction in the on-patent commercial manufacturing and generic active pharmaceutical ingredient (API) business.

Stock Trading

Maximise Returns by Investing in the Right Companies

By – The Economic Times, Get Certified By India’s Top Business News Brand
Stock Trading

Market 104: Options Trading: Kickstart Your F&O Adventure

By – Saketh R, Founder- QuickAlpha, Full Time Options Trader
Stock Trading

Technical Analysis for Everyone – Technical Analysis Course

By – Abhijit Paul, Technical Research Head, Fund Manager- ICICI Securities
Stock Trading

Stock Markets Made Easy

By – elearnmarkets, Financial Education by StockEdge
Stock Trading

Renko Chart Patterns Made Easy

By – Kaushik Akiwatkar, Derivative Trader and Investor
Stock Trading

Market 101: An Insight into Trendlines and Momentum

By – Rohit Srivastava, Founder- Indiacharts.com
Stock Trading

Markets 102: Mastering Sentiment Indicators for Swing and Positional Trading

By – Rohit Srivastava, Founder- Indiacharts.com
Stock Trading

Dow Theory Made Easy

By – Vishal Mehta, Independent Systematic Trader
Stock Trading

Market 103: Mastering Trends with RMI and Techno-Funda Insights

By – Rohit Srivastava, Founder- Indiacharts.com
Stock Trading

ROC Made Easy: Master Course for ROC Stock Indicator

By – Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading

Heikin Ashi Trading Tactics: Master the Art of Trading

By – Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert
Stock Trading

RSI Made Easy: RSI Trading Course

By – Souradeep Dey, Equity and Commodity Trader, Trainer
Stock Trading

Introduction to Technical Analysis & Candlestick Theory

By – Dinesh Nagpal, Full Time Trader, Ichimoku & Trading Psychology Expert

The complex hospital generics segment grew 14% YoY to Rs 654 crore led by volume growth in inhalation anesthesia portfolio and India consumer health business gained 10% to Rs 278 crore.”FY25 so far has been a steady year for the company with revenue growth of 14% and EBITDA growing at 20%,” said Nandini Piramal, chairperson, Piramal Pharma.

“Our CDMO business continues to deliver robust performance with 18% revenue growth along with EBITDA margin improvement in 9MFY25 – this performance was largely led by innovation related work. Our CHG business registered an early-teen revenue growth during the quarter on the back of strong volume growth in our Inhalation Anesthesia portfolio. In our ICH business, power brands continue to register about 19% growth,” Piramal added.

Forrás: eredeti cikk

Ezt a cikket a SasFly.net hozta neked. Jogi kérdésekben hazai ügyekben az fabianlaw.hu, nemzetközi jogi képviselet esetén a amerikaiugyved.hu csapata áll rendelkezésedre.